Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Healthcare IT in 2025: Triage for the Age of AI
Amid the chaos and confusion of healthcare IT in our age of AI, a triage concept may be the best guide for organizations fighting to stray strong and capable in 2025 and beyond.
The Evolving Landscape of Medicaid and CHIP: Implications for Children’s Oral Health
Medicaid and CHIP facilitate necessary access to oral health services, which helps to bridge the gap in dental care for children from low- and moderate-income families. By providing coverage, it ensures that socioeconomic status does not hinder a child’s ability to receive necessary dental services.
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
December saw a slew of executive hires, promotions, exits and layoffs across the healthcare industry. For example, companies like Humana and Mayo Clinic hired new C-suite leaders, organizations including Atlantic Health System and Amwell are saying goodbye to key executives, and firms like CVS Health and Optum announced rounds of job cuts.
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug.